Monday, February 10, 2025

VACCIMEL Vaccine Amplifies Immune Defense in Melanoma Patients

Similar articles

A breakthrough in melanoma treatment has emerged with the introduction of VACCIMEL, a therapeutic cancer vaccine designed to bolster the immune system’s ability to fight cancer. This innovative vaccine consists of four irradiated allogeneic human melanoma cell lines selected to present a diverse array of tumor-associated antigens.

Table of Contents

Subscribe Weekly Market Access News

* indicates required

Robust T Cell Activation

Clinical trials have revealed that administering VACCIMEL in the adjuvant setting significantly extends the distant-metastasis-free survival of patients with cutaneous melanoma. Enhanced T cell responses targeting both tumor-associated antigens and unique neoantigens specific to each patient were observed during the treatment period.

Extensive Genomic Profiling

To investigate the range of immunogens presented by VACCIMEL, researchers conducted whole-exome sequencing on tumor and germinal samples from four vaccinated patients, alongside analysis of the vaccine cells. This comprehensive genomic approach identified an average of 9,481 non-synonymous coding variants per patient, highlighting the vaccine’s potential to introduce a vast number of antigens.

Inferences:

  • VACCIMEL’s extensive variant repertoire may enhance immune system recognition of cancer cells.
  • Limited overlap between vaccine variants and patient tumors suggests personalized immune targeting.
  • High tumor mutational burden in some patients indicates a stronger correlation with vaccine-induced antigens.

Immune response assessments using IFNI3 ELISpot assays demonstrated that patients developed highly diverse T cell responses against VACCIMEL peptides. Notably, effector T cells targeting the patients’ own tumor antigens, including neoantigens and TAA, were more prevalent than those targeting vaccine-specific antigens. However, the immunogenic epitopes varied across patients despite shared HLA profiles, and T cell responses showed temporal fluctuations.

A positive correlation was established between the expression levels of VACCIMEL antigens and the intensity of T cell responses, suggesting that higher antigen expression enhances immune activation. This finding underscores the vaccine’s efficacy in presenting antigens to the immune system effectively.

VACCIMEL successfully engages the immune system to recognize a wide spectrum of antigens, including those not inherently present in the patient’s tumors. This dual targeting ensures that immune responses against vaccine-specific epitopes do not impede the recognition and elimination of critical tumor neoantigens and TAA.

The development of VACCIMEL marks a significant advancement in personalized cancer immunotherapy. By leveraging a broad antigenic profile and stimulating diverse T cell responses, VACCIMEL has the potential to improve therapeutic outcomes for melanoma patients. Future research should focus on optimizing antigen selection and understanding the long-term immune dynamics to fully harness the vaccine’s benefits.

Source

You can follow our news on our Telegram, LinkedIn and Youtube accounts.


This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article